Genomic alterations of ERBB receptors in cancer: clinical implications

Mishra, Rosalin; Hanker, Ariella B.; Garrett, Joan T.

doi:10.18632/oncotarget.22825

Cited by 105 publications

(105 citation statements)

References 148 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, EGFR family receptors are amplified and/or mutated in various human tumors, including gliomas, non-small-cell lung carcinoma, breast, gastric, and ovarian cancers. [205][206][207] Activation of EGFR results in the recruitment of Grb2, a SH2 domain protein complexed with the guanine exchange factor son-of-sevenless (Sos), to the tyrosine-phosphorylated EGFR. [205][206][207] Activation of EGFR results in the recruitment of Grb2, a SH2 domain protein complexed with the guanine exchange factor son-of-sevenless (Sos), to the tyrosine-phosphorylated EGFR.…”

Section: Rtks Cancer Cells and Primary Ciliamentioning

confidence: 99%

Primary Cilia as Signaling Hubs in Health and Disease

et al. 2018

View full text Add to dashboard Cite

Primary cilia detect extracellular cues and transduce these signals into cells to regulate proliferation, migration, and differentiation. Here, the function of primary cilia as signaling hubs of growth factors and morphogens is in focus. First, the molecular mechanisms regulating the assembly and disassembly of primary cilia are described. Then, the role of primary cilia in mediating growth factor and morphogen signaling to maintain human health and the potential mechanisms by which defects in these pathways contribute to human diseases, such as ciliopathy, obesity, and cancer are described. Furthermore, a novel signaling pathway by which certain growth factors stimulate cell proliferation through suppression of ciliogenesis is also described, suggesting novel therapeutic targets in cancer.

show abstract

Section: Rtks Cancer Cells and Primary Ciliamentioning

confidence: 99%

Primary Cilia as Signaling Hubs in Health and Disease

et al. 2018

View full text Add to dashboard Cite

show abstract

“…HER2/neu gene amplification and/or protein overexpression are found in many human cancers, such as breast, bladder, and gastric cancer. Five HER2 inhibitors are currently FDA-approved to treat HER2-amplified/overexpressing breast cancers 48. In 2008 Karam et al reviewed the data available on VPD, after describing success treating a recurrent, symptomatic case with trastuzumab.…”

Section: Resultsmentioning

confidence: 99%

Reviewing vulvar Paget’s disease molecular bases. Looking forward to personalized target therapies: a matter of CHANGE

Mantovani

Fagotti

Franchi

et al. 2019

Int J Gynecol Cancer

View full text Add to dashboard Cite

ObjectivesTo review the published literature on vulvar Paget’s disease (VPD) molecular bases, aiming to support the need for tailored treatment in women affected by this 'orphan' tumor.MethodsMEDLINE-PubMed and Scopus were interrogated using the following algorithm: (extramammary OR extra mammary OR vulvar) AND (paget OR pagets OR paget's) AND (molecular OR biological OR marker OR protein OR target OR expression). The inclusion criteria for papers were: peer-reviewed English-language journals, articles published in the last 30 years, studies focused on fixed research questions, quality assessment on the basis of the relevance and contribution to the selected topics.ResultsA total of 42 studies were selected, providing the following results. Molecular markers implicated in cell cycle transitions seem to be related to prognosis and could help to tailor conventional treatments. Fragmented but consistent preliminary data exist on hormonal receptor expression, ERBB2 amplification/overexpression and abnormal vascular proliferation, offering a concrete possibility for target therapy trials. Conversely, other fields linked to the possible use of immunotherapy are currently relatively unexplored, such as the tumor 'immune contexture', programmed death ligand-1 (PD-L1) expression and defects in the mismatch repair system, which is involved in genomic instability and potentially promotes a consistent response to treatment.ConclusionsAdditional effort is needed to further characterize these aspects. Centralization of patients in dedicated units would be beneficial for concentrating patient numbers, collecting valuable clinical data and conducting clinical trials. Interdisciplinary study platforms should be developed and integrated into wider multicentric networks.

show abstract

“…A report suggests that ERBB2 and ERBB3 are down-regulated by DNA-damaging agent such as cisplatin via ERK and p38 signaling pathway [26]. It is also demonstrated that ERBB3 is involved in resistance to EGFR or ERBB2 targeted therapy for cancer [27]. Furthermore, the study of nanoparticles targeting ERBB2 and microRNA21 suggests the importance of ERBB signaling in cancer [28].…”

Section: Discussionmentioning

confidence: 99%

Molecular Network Pathway Of ERBB In Diffuse-Type Gastric Cancer, Mesenchymal Stem Cells And Epithelial-Mesenchymal Transition

Tanabe¹

2018

J Clin Epigenet

View full text Add to dashboard Cite

Epithelial-mesenchymal transition (EMT) is related to malignancy and metastasis in cancer. The molecular networks including tyrosine kinases are altered in gastric cancer (GC). This study aims to reveal the role of ERBBs (erb-b2 receptor tyrosine kinases) in EMT, and generate the molecular network pathway of ERBBs in diffusetype GC and mesenchymal stem cells (MSCs). The expression of ERBB genes was analyzed in MSCs and diffuse-type GC which has mesenchymal characteristics compared to intestinal-type GC. The signaling and molecular network of ERBB was analyzed using several databases, including cBioPortal for Cancer Genomics, Kyoto Encyclopedia of Genes and Genomes (KEGG), BioGRID and VaProS. ERBB2 and ERBB3 gene expression were up-regulated in diffuse-type GC compared to MSCs. The ERBB3 molecular network includes epidermal growth factor receptor (EGFR), cadherin 1 (CDH1), catenin beta 1 (CTNNB1) and EPH receptor A5 (EPHA5). These results demonstrate the importance of the ERBB network in cancer signaling, and revealed a ERBB3 network pathway model in diffuse-type GC and MSCs, and EMT.Keywords: Epithelial-mesenchymal transition; Gastric cancer; Mesenchymal stem cell; ERBB; Stem cell cancer (GC) [7]. Mutations in extracellular domains of ERBB2 are suggested to be oncogenic in lung cancer [8].Since previous reports have demonstrated that the ERBB members are involved in cancer and stem cell networks, it is important to elucidate the role of ERBBs in EMT and cancer resistance. To further reveal the mechanism of EMT in cancer and stem cells, we investigated the expression of ERBB genes in mesenchymal stem cells (MSCs) and diffuse-type GC, and generated ERBB network pathway model. Materials and Methods Gene expression analysis of MSCs and GCGene expression in MSCs (6 early-and 6 late-stage cultures, n=12) and diffuse-type GC (n=5) was analyzed with GeneChip® Human Genome U133 Plus 2.0 microarray (Affymetrix, Santa Clara, California, USA), as previously described [1,9,10]. Briefly, total purified cellular RNA was biotinylated and hybridized to the microarray. Cell cultureHuman MSCs from bone marrow (Lonza, Walkersville, MD, USA) were cultured in MSC growth medium (MSCGM; Lonza #PT-3001; MSC basal medium supplemented with mesenchymal cell growth supplement, L-glutamine and penicillin/streptomycin) at 37°C in a CO 2 (5%) incubator. Cells were passaged according to the manufacturer's protocol, however a slight modification was made to use trypsin-EDTA solution (Lonza #CC-3232). Lot numbers of the human MSC batches were as follows: #4F1127, #4F0312, #5F0138, #4F1560, #4F0591 and #4F0760. Informed consent was obtained for Poietics human MSC systems (Lonza) [10]. Passage numbers of MSC cultures were #4 and #22 for #4F1127, #4 and #28 for #4F0312, #4 and #24 for #5F0138, #5 and #28 for #4F1560, #4 and #28 for #4F0591, and #4 and #28 for #4F0760. Diffuse-Type GC tissuesDiffuse-type GC tissues were originally provided by the National Cancer Center Hospital after obtaining written informed consent from each patient and ...

show abstract

Genomic alterations of ERBB receptors in cancer: clinical implications

Cited by 105 publications

References 148 publications

Primary Cilia as Signaling Hubs in Health and Disease

Primary Cilia as Signaling Hubs in Health and Disease

Reviewing vulvar Paget’s disease molecular bases. Looking forward to personalized target therapies: a matter of CHANGE

Molecular Network Pathway Of ERBB In Diffuse-Type Gastric Cancer, Mesenchymal Stem Cells And Epithelial-Mesenchymal Transition

Contact Info

Product

Resources

About